# OnCo record vistogard-studies-1-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/vistogard-studies-1-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "vistogard-studies-1-2", "NCT01432301" ;
  schema:name "Vistogard Studies 1 and 2"@en ;
  schema:alternateName "401.10.001"@en, "Uridine triacetate expanded-access studies"@en ;
  schema:description "Vistogard Studies 1 and 2 gave an oral uridine antidote quickly after a fluorouracil or capecitabine overdose or early severe toxicity; almost everyone treated survived, while most people in an earlier group given supportive care alone had died, and the studies were the main evidence for the US approval of Vistogard."@en ;
  schema:url <https://onco.cc/trials/vistogard-studies-1-2/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01432301>, <https://doi.org/10.1002/cncr.30321>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=269f7363-63ed-444e-85f1-f0009e44818b> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:related <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/uridine-triacetate/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vistogard-cancer-2017/> .